Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.26), $0.11 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $28.5 million versus the consensus estimate of $19.76 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.